Primary sclerosing cholangitis Market will exhibit a CAGR of around 4.02% in the forecast period 2021-2028 and segemented on the basis of type, Treatment type, Symptom Control, End user, & Country.
A recent study published in the New England Journal of Medicine suggests that the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar may hold significant benefits for patients diagnosed with primary biliary cholangitis. Led by Gideon M. Hirschfield, Ph.D., from the University Health Network in Toronto, the phase 3 clinical trial involved 193 patients with primary
Primary sclerosing cholangitis Market will exhibit a CAGR of around 4.02% in the forecast period 2021-2028 and segemented on the basis of type, Treatment type, Symptom Control, End user, & Country.
Primary sclerosing cholangitis Market will exhibit a CAGR of around 4.02% in the forecast period 2021-2028 and segemented on the basis of type, Treatment type, Symptom Control, End user, & Country.